Parkinson's Disease Research Education and Clinical Centers (PADRECC): Background and overview

NeuroRehabilitation

Volumn 20, Issue 3, 2005, Pages 153-160

  Diaz, Natalie ^a   Bronstein, Jeff M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAREGIVER; COMMUNITY; EDUCATION; EVALUATION; HEALTH CARE MANAGEMENT; HEALTH CARE QUALITY; HEALTH CARE SYSTEM; HEALTH CENTER; HEALTH SERVICE; HUMAN; MEDICAL INFORMATION; MEDICAL RESEARCH; MOTOR DYSFUNCTION; OCCUPATION; PARKINSON DISEASE; REGISTER; REVIEW; STEM CELL; TELEMEDICINE; VETERAN; VOCATIONAL EDUCATION;

EID: 30644465474     PISSN: 10538135     EISSN: None     Source Type: Journal    
DOI: 10.3233/nre-2005-20302     Document Type: Review

References (15)

1. E.M. Cheng, A. Siderof, K. Swarztrauber, M. Eisa, M. Lee and B.G. Vickrey, Development of quality of care indicators for Parkinson's disease, Movement Disorders 19(2) (Feb 2004), 136-150.
2. E.A. Chrischilles, L.M. Rubenstein, M.D. Voelker, R.B. Wallace and R.L. Rodnitzky, The health burdens of Parkinson's disease, Movement Disorders 13 (1998), 406-413.
3. J.E. Duda, B.I. Giasson, M.E. Mabon, V.M. Lee and J.Q. Trojanoski, Novel antibodies to synuclein show abundant striatal pathology in lewy body disorders, Ann Neurol 52(2) (May 2002), 205-210.
4. H. Gage, A. Hendricks, S. Zhang and L. Kazis, The relative health related quality of life of veterans with Parkinson's disease, J Neurology, Neurosurg Psychiatry 74 (2003), 163-169.
5. H. Gage and L. Storey, Rehabilitation for Parkinson's disease: a systemic review of available evidence, Clinical Rehab 18(5) (Aug 2004), 463-482.
6. M.M. Hoehn and M.D. Yahr, Parkinsonism: onset, progression and mortality, Neurology 17 (1967), 427-442.
7. J.F. Houde, S. Nagarajan, T. Heinks, C.M. Fox, L.O. Ramig and W.J. Marks, The effect of voice therapy on feedback control in parkinsonian speech, Movement Disorders 19(Supplenmt 9) (2004), S403.
8. The Parkinson Study Group, Transdermal dopaminergic D2 receptor agonist therapy in Parkinson's disease with N-0923 TDS: A double-blind placebo controlled study, Movement Disorders 16 (2001), 459-463.
9. The Parkinson Study Group, A controlled trial of rasagiline in early PD: The TEMPO Study, Arch Neurol 59(12) (Dec 2002), 1937-1943.
10. A. Schrag, M. Jahanshahi and N. Quinn, How does Parkinson's disease affect quality of life? A comparison with quality of life in the general population, Movement Disorders 15(6) (Nov 2000), 1112-1118.
11. P.A. Starr, W.J. Marks, Jr., M. Mori, G. Rau, D. Simmons, N. Lindsey and R.S. Turner, Pallidal neuronal activity in 20 patients with dystonia: comparison with Parkinson's disease and normal Macaque, Movement Disorders 19(Supplement 9) (2004), S90.
12. C.M. Tanner and S.M. Goldman, Epidemiology of Parkinson's Disease, Neurology Clinics 14 (1996), 317-335.
13. P. Trend, J. Kaye, H. Gage, C. Owen and D. Wade, Short-term effectiveness of intensive multidisciplinary rehabilitation for people with Parkinson's disease and their carers, Clinical Rehab 16(7) (Nov 2002), 717-725.
14. D. Weintraub, P.J. Moberj, J.E. Duda, I.R. Katz and M.B. Stern, Effects of neuropsychiatric and other nonmotor symptoms on disability in Parkinson's disease, J Am Geriatric Soc 52(5) (May 2004), 784-788.
15. D. Weintraub, P.J. Moberj, J.E. Duda, I.R. Katz and M.B. Stern, Recognition and treatment of depression in Parkinson's disease, J Geriatric Psychiatry Neurol 16(3) (Sep 2003), 178-183.